Prime Medicine PRME Operating lease right-of-use asset amortization
Operating lease right-of-use asset amortization at other companies
Other financials
Where this comes from
Reported directly by Prime Medicine in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Prime Medicine's operating lease right-of-use asset amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Prime Medicine's operating lease right-of-use asset amortization?
- Prime Medicine (PRME) reported operating lease right-of-use asset amortization of $2.84M in Q1 2026.
- How has Prime Medicine's operating lease right-of-use asset amortization changed year-over-year?
- Prime Medicine's operating lease right-of-use asset amortization increased by 17.8% year-over-year, from $2.41M to $2.84M.
- What is the long-term trend for Prime Medicine's operating lease right-of-use asset amortization?
- Over 3 years (2022 to 2025), Prime Medicine's operating lease right-of-use asset amortization has grown at a -0.3% compound annual growth rate (CAGR), from $9.79M to $9.7M.